OBJECTIVES: Emerging data suggest that vitamin D has a significant role in inflammatory bowel disease (IBD). Prospective data evaluating the association of vitamin D serum status and disease course are lacking. We sought to determine the relationship between vitamin D status and clinical course of IBD over a multiyear time period. METHODS: IBD patients with up to 5-year follow-up from a longitudinal IBD natural history registry were included. Patients were categorized according to their mean serum 25-OH vitamin D level. IBD clinical status was approximated with patterns of medication use, health-care utilization, biochemical markers of inflammation (C-reactive protein (CRP) and erythrocyte sedimentation rate (ESR)), pain and clinical disease activity scores, and health-related quality of life. RESULTS: A total of 965 IBD patients (61.9% Crohn's disease, 38.1% ulcerative colitis) formed the study population (mean age 44 years, 52.3% female). Among them, 29.9% had low mean vitamin D levels. Over the 5-year study period, subjects with low mean vitamin D required significantly more steroids, biologics, narcotics, computed tomography scans, emergency department visits, hospital admissions, and surgery compared with subjects with normal mean vitamin D levels (P<0.05). Moreover, subjects with low vitamin D levels had worse pain, disease activity scores, and quality of life (P<0.05). Finally, subjects who received vitamin D supplements had a significant reduction in their health-care utilization. CONCLUSIONS: Low vitamin D levels are common in IBD patients and are associated with higher morbidity and disease severity, signifying the potential importance of vitamin D monitoring and treatment.
OBJECTIVES: Emerging data suggest that vitamin D has a significant role in inflammatory bowel disease (IBD). Prospective data evaluating the association of vitamin D serum status and disease course are lacking. We sought to determine the relationship between vitamin D status and clinical course of IBD over a multiyear time period. METHODS: IBD patients with up to 5-year follow-up from a longitudinal IBD natural history registry were included. Patients were categorized according to their mean serum 25-OHvitamin D level. IBD clinical status was approximated with patterns of medication use, health-care utilization, biochemical markers of inflammation (C-reactive protein (CRP) and erythrocyte sedimentation rate (ESR)), pain and clinical disease activity scores, and health-related quality of life. RESULTS: A total of 965 IBD patients (61.9% Crohn's disease, 38.1% ulcerative colitis) formed the study population (mean age 44 years, 52.3% female). Among them, 29.9% had low mean vitamin D levels. Over the 5-year study period, subjects with low mean vitamin D required significantly more steroids, biologics, narcotics, computed tomography scans, emergency department visits, hospital admissions, and surgery compared with subjects with normal mean vitamin D levels (P<0.05). Moreover, subjects with low vitamin D levels had worse pain, disease activity scores, and quality of life (P<0.05). Finally, subjects who received vitamin D supplements had a significant reduction in their health-care utilization. CONCLUSIONS: Low vitamin D levels are common in IBD patients and are associated with higher morbidity and disease severity, signifying the potential importance of vitamin D monitoring and treatment.
Authors: M T Abreu; V Kantorovich; E A Vasiliauskas; U Gruntmanis; R Matuk; K Daigle; S Chen; D Zehnder; Y-C Lin; H Yang; M Hewison; J S Adams Journal: Gut Date: 2004-08 Impact factor: 23.059
Authors: D McCarthy; P Duggan; M O'Brien; M Kiely; J McCarthy; F Shanahan; K D Cashman Journal: Aliment Pharmacol Ther Date: 2005-05-01 Impact factor: 8.171
Authors: Maria Stio; Maria Martinesi; Sara Bruni; Cristina Treves; Giuseppe d'Albasio; Siro Bagnoli; Andrea G Bonanomi Journal: Int Immunopharmacol Date: 2006-02-23 Impact factor: 4.932
Authors: S P Jørgensen; J Agnholt; H Glerup; S Lyhne; G E Villadsen; C L Hvas; L E Bartels; J Kelsen; L A Christensen; J F Dahlerup Journal: Aliment Pharmacol Ther Date: 2010-05-11 Impact factor: 8.171
Authors: Jessica R de Bruyn; Rosanne van Heeckeren; Cyriel Y Ponsioen; Gijs R van den Brink; Mark Löwenberg; Albert J Bredenoord; Gerard Frijstein; Geert R D'Haens Journal: J Crohns Colitis Date: 2014-03-23 Impact factor: 9.071
Authors: John Gubatan; Shuji Mitsuhashi; Maria Serena Longhi; Talia Zenlea; Laura Rosenberg; Simon Robson; Alan C Moss Journal: Cytokine Date: 2018-01-08 Impact factor: 3.861
Authors: Vassil Dimitrov; Manuella Bouttier; Giselle Boukhaled; Reyhaneh Salehi-Tabar; Radu G Avramescu; Babak Memari; Benedeta Hasaj; Gergely L Lukacs; Connie M Krawczyk; John H White Journal: J Biol Chem Date: 2017-10-23 Impact factor: 5.157
Authors: Alyce J M Anderson; Benjamin Click; Claudia Ramos-Rivers; Dmitriy Babichenko; Ioannis E Koutroubakis; Douglas J Hartman; Jana G Hashash; Marc Schwartz; Jason Swoger; Arthur M Barrie; Michael A Dunn; Miguel Regueiro; David G Binion Journal: Dig Dis Sci Date: 2016-09-12 Impact factor: 3.199